

# Non-eosinophilic asthma: importance and possible mechanisms

J Douwes, P Gibson, J Pekkanen, N Pearce

*Thorax* 2002;**57**:643–648

There is increasing evidence that inflammatory mechanisms other than eosinophilic inflammation may be involved in producing the final common pathway of enhanced bronchial reactivity and reversible airflow obstruction that characterises asthma. A review of the literature has shown that, at most, only 50% of asthma cases are attributable to eosinophilic airway inflammation. It is hypothesised that a major proportion of asthma is based on neutrophilic airway inflammation, possibly triggered by environmental exposure to bacterial endotoxin, particulate air pollution, and ozone, as well as viral infections. If there are indeed two (or more) subtypes of asthma, and if non-eosinophilic (neutrophil mediated) asthma is relatively common, this would have major consequences for the treatment and prevention of asthma since most treatment and prevention strategies are now almost entirely focused on allergic/eosinophilic asthma and allergen avoidance measures, respectively. It is therefore important to study the aetiology of asthma further, including the underlying inflammatory profiles.

inconsistent association between the prevalence of asthma and the prevalence of atopy.<sup>4</sup> A recent comparison of asthma and atopy in 9–11 year old children in Albania and the UK<sup>6</sup> is particularly interesting in this regard. Large differences were seen in the prevalence of current wheeze (4.4% and 9.7%, respectively) and exercise induced bronchial reactivity (0.8% and 5.4%) but not in skin prick test positivity (15.0% and 17.8%), suggesting that considerable variations in the prevalence of asthma can occur without differences in the frequency of atopy. Furthermore, treatment with antibodies that neutralise IgE (anti-IgE) are only partially effective in asthma,<sup>7–12</sup> adding to the evidence that other inflammatory mechanisms operate in asthma and that the role of IgE may be less important than has often been assumed.<sup>13</sup> Several animal studies also support this view and, in addition, question the relative importance of IgE in the pathogenesis of allergic asthma.<sup>14–17</sup>

Recent studies using sputum induction and/or bronchoalveolar lavage (BAL) techniques to measure and characterise airways inflammation in asthmatic subjects have shown that at least some, and potentially a substantial proportion, of cases have an underlying pathology that is clearly different from that observed in “classic” allergic asthma.<sup>18–24</sup> Specifically, patients are observed to have severe and persistent asthma in the absence of eosinophilic inflammation, and may experience an exacerbation of asthma without an increase in eosinophilic inflammation.<sup>24</sup> In addition, it is well known that non-allergic asthma is quite common in occupational populations.<sup>25</sup> These studies, from a variety of different laboratories, clearly demonstrate the existence of non-eosinophilic asthma. This raises the question as to the role of non-allergic inflammatory mechanisms in the pathophysiology of asthma, and whether these may be involved in a substantial proportion of asthma cases in the general population.

In this review we try to quantify the contribution of non-eosinophilic asthma in the general population, to explore whether non-allergic occupational asthma can be used as a model for this type of asthma in the general population, and discuss potentially relevant exposures and mechanisms that may result in non-eosinophilic asthma.

## DEFINITIONS

### Atopy

We consider “atopy” as IgE mediated sensitisation to “common allergens” such as house dust mite, pet, and various food allergens. Atopy is usually assessed by skin prick tests or specific serum IgE

The prevalence of asthma is increasing worldwide, but the reasons for the striking increases are unclear.<sup>1</sup> The pathophysiological mechanisms involved in the development of asthma are also not completely understood. Asthma is known to involve a heterogeneous airway inflammatory response where many cells play a part.<sup>2</sup> In recent decades allergic mechanisms have been closely studied and defined. Consequently, asthma has almost universally been regarded as an atopic disease involving allergen exposure, allergic (IgE mediated) sensitisation with a Th2 CD4+ lymphocyte response and subsequent IL-5 mediated eosinophilic airways inflammation, resulting in enhanced bronchial reactivity<sup>3</sup> and eventually in reversible airflow obstruction (asthma).

There is now increasing evidence that other inflammatory mechanisms may be involved in producing the final common pathway of enhanced bronchial reactivity and reversible airflow obstruction that characterises asthma. In a recent systematic review of population based studies we have shown that the proportion of asthma cases that are attributable to atopy is usually less than 50%.<sup>4–5</sup> Standardised comparisons across populations or time periods show only a weak and

See end of article for authors' affiliations

Correspondence to:  
Dr J Douwes, IRAS, PO Box  
80176, 3508 TD, Utrecht,  
The Netherlands;  
j.douwes@iras.uu.nl

measures of sensitisation to common allergens. However, a positive test only indicates that a subject is sensitised against a common allergen but does not constitute proof that symptoms experienced by the subject are caused by allergic (IgE) mediated mechanisms.

### Asthma

We consider asthma as a heterogeneous chronic inflammatory disorder of the airways involving airflow limitation that is at least partly reversible and which results in recurrent episodes of symptoms such as wheezing, breathlessness, chest tightness, and cough.<sup>2</sup> We define eosinophilic asthma as symptomatic airway inflammation characterised by the presence of eosinophils in the airways. Non-eosinophilic asthma then represents symptomatic asthma in the absence of eosinophilic airway inflammation. This definition, based on the underlying pattern of airway inflammation, can now be studied relatively easy using sputum induction techniques.<sup>26–27</sup> Eosinophilic inflammation is generally considered to be the main feature of allergic asthmatic airways and is presumed to be crucial in the pathogenesis of allergic asthma.<sup>28</sup> In addition to eosinophils, interleukin (IL)-5 and possibly IL-4 play a key role in allergic asthma (IL-5 stimulates the growth, differentiation and activation of the eosinophils, and IL-4 stimulates B cells to IgE production and naïve Th0 cells to differentiate toward a Th2 state), and thus increased levels of IL-5 and IL-4 (in combination with raised eosinophil levels) may be used as other “specific” markers.

### PROPORTION OF NON-EOSINOPHILIC ASTHMA IN THE GENERAL POPULATION

Using the classification described above (based on the presence or absence of eosinophils in bronchial biopsy specimens, BAL fluid, or sputum), we have attempted to quantify the proportion of non-eosinophilic asthmatics in the general population. However, previous studies on airways inflammation have been conducted mainly on selected populations—that is, subjects attending asthma clinics, severe asthmatics, atopic asthmatics, asthmatics with bronchial hyperreactivity (BHR), etc—and only a few were conducted in a random sample of asthmatic subjects. These studies therefore give only a crude estimate of the proportion of asthma which is non-eosinophilic in selected populations.

For the purpose of this review we have selected from Medline studies from 1995 onwards with data on eosinophil levels in biopsy specimens, BAL fluid, or sputum of asthmatic subjects where the subjects were not clearly selected on the basis of atopic characteristics (positive skin prick tests or IgE determinations), and where data were presented so that the subjects could be classified as eosinophilic or non-eosinophilic asthmatics. Cut off values used to define eosinophilic and non-eosinophilic asthma were the same as those reported in the original studies (2–4%) or, when the authors did not define a cut off level, we used 2% based on the upper normal limit for eosinophil counts in sputum as previously published.<sup>29–30</sup> Table 1 summarises the proportion of asthmatic subjects with eosinophilic inflammation for all eligible studies. The weighed mean proportion of subjects with eosinophilic asthma was 51%, so 49% had non-eosinophilic asthma. Exclusion of infant wheezers<sup>19</sup> who may not be truly asthmatic did not significantly change the overall estimate (52% versus 51% eosinophilic asthma).

This estimate of the percentage of asthmatics that are “attributable” to eosinophilia is probably an overestimate since non-asthmatic control subjects may have eosinophilia as well, and thus not all asthmatic subjects with eosinophilia necessarily have asthma due to eosinophilia (just as not all asthmatic subjects with atopy have asthma due to atopy<sup>4</sup>). Only six studies reported findings for non-asthmatic controls. In two studies 20% of the non-asthmatic controls had

increased eosinophil levels,<sup>19–20</sup> in one 9.4% had increased sputum eosinophil levels,<sup>42</sup> and in the other three studies none of the controls had raised sputum eosinophil levels.<sup>23–31–35</sup> For the studies with 20% and 9.4% eosinophil positive controls we calculated the population attributable risk (PAR)<sup>4</sup> to estimate the true proportion of asthma cases that were attributable to eosinophilia. The PARs for the study by Gibson *et al*<sup>20</sup> were 26% and 51%, respectively, compared with the crude estimates (the proportion of asthmatics with eosinophilia) of 41% for children with current symptoms and 62% for children with BHR. The PAR for another recent study by Gibson *et al*<sup>42</sup> in children with current wheeze was 36% compared with a crude estimate of 45%, while in the study by Marguet *et al*<sup>19</sup> the PAR was 46% compared with a crude estimate of 57% (for children).

This suggests that our estimate of 49% of non-eosinophilic asthma is conservative. On the other hand, the figure of 51% for eosinophilic asthma would be an underestimate (and the figure of 49% for non-eosinophilic asthma would be an overestimate) if a significant proportion of eosinophilic asthmatic subjects did not have eosinophilia at the time they were studied, either because of treatment with corticosteroids or because they had no current symptoms. However, as shown in table 1, the percentage was still relatively low even in asthmatic subjects who were not receiving corticosteroids. Also, the proportion of eosinophilic asthmatic subjects was equally “low” in those with current symptoms (table 1), indicating that this hypothesis was unlikely to account for our findings.

“allergic mechanisms may not be the only and/or the most important underlying mechanism for asthma”

The weighed mean percentage of eosinophilic asthmatics in children was 46% compared with 53% in adults. It is therefore clear that non-eosinophilic asthma is very common both in children and adults. In addition, although it has been speculated that non-eosinophilic inflammation may be a typical characteristic for severe asthma,<sup>18–36</sup> the findings in table 1 show that non-eosinophilic asthma is also very common in mild and moderate asthma. Of particular interest is the study by Gibson *et al*<sup>20</sup> in 56 asthmatic children who had experienced symptoms in the previous 2 weeks, since this is a study in a *random* population of asthmatics. The estimate of 41% (with a PAR of “only” 26%) suggests that approximately 60% (or more) of all asthma cases in children could be attributable to non-allergic or non-eosinophilic mechanisms. This was confirmed in another random population study conducted by the same group.<sup>42</sup> Restricting the population to only those children with BHR resulted in an increase in the proportion of eosinophil positive asthmatics to 62% (PAR 51%),<sup>20</sup> suggesting that BHR is associated with eosinophilic asthma but less so with non-eosinophilic asthma. This has also been shown previously by others.<sup>24</sup>

It is striking that in most studies non-eosinophilic asthma was associated with increased neutrophil and IL-8 levels,<sup>18–19–21–36–43–44</sup> which suggests that non-allergic neutrophil driven airways inflammation was the underlying mechanism for non-eosinophilic asthma. Interestingly, the inflammatory profile appears to be very similar to that described for non-eosinophilic occupational asthma (see below), and is consistent with activation of innate immune mechanisms mediating the inflammatory process in non-eosinophilic asthma (fig 1).

### NON-ALLERGIC OCCUPATIONAL ASTHMA

Our focus in this review is on asthma in the general population, but it is interesting also specifically to consider studies of occupational asthma since these provide further evidence of the importance of non-allergic mechanisms for

**Table 1** Proportion of asthmatics with lung eosinophilia

Study	Case definition*	Method	Definition of eosinophilic and non-eosinophilic asthma based on cut off values**	Eosinophilic asthma	
				No	%
<i>Studies in adults:</i>					
Fahy <i>et al</i> (1995) <sup>32</sup>	Acute severe asthma	Sputum	2% eosinophils¶	18	50%
Turner <i>et al</i> (1995) <sup>24</sup>	Mild asthma with exacerbation in past 2 weeks	Sputum†	4% eosinophils¶	34	47%
Pizzichini <i>et al</i> (1996) <sup>27</sup>	Stable asthma	Sputum	2% eosinophils¶	19	58%
Wenzel <i>et al</i> (1999) <sup>18</sup>	Severe asthma, corticosteroid (CS) dependent	Bronchial biopsy	Mean eosinophil count +2SD (exact value not given)	34	59%
Pavord <i>et al</i> (1999) <sup>22</sup>	Asthma patients treated with $\beta_2$ agonists	Sputum	3% eosinophils¶	23	61%
Pavord <i>et al</i> (1999) <sup>33</sup>	Asthma of variable severity	Sputum†	3% eosinophils	26	88%
Jatakanon <i>et al</i> (1999) <sup>23</sup>	Persistent asthma of variable severity: • Mild persistent • Moderate persistent • Severe persistent	Sputum	2% eosinophils	55 23 16 16	60% 78% 38% 56%
Lemière <i>et al</i> (1999) <sup>34</sup>	Asthma of variable severity	Sputum	2% eosinophils	6	33%
Berlyne <i>et al</i> (1999) <sup>30</sup>	Asthma of variable severity	Sputum†	2% eosinophils Mean eosinophil count + 2SD ( $87 \times 10^3/g$ )	84 84	52% 82%
Tarodo de la Fuente <i>et al</i> (1999) <sup>35</sup>	Asthma of variable severity • Mild untreated • Moderate treated with ICS • Severe CS dependent	Sputum	2% eosinophils	38 9 12 17	34% 22% 25% 47%
Ordoñez <i>et al</i> (2000) <sup>36</sup>	Acute severe asthma	Tracheal aspirates during intubation	2% eosinophils¶	10	70%
Wark <i>et al</i> (2000) <sup>37</sup>	Asthma of variable severity: • Not treated with ICS • Treated with ICS	Sputum	2.75% eosinophils	32 15 17	44% 67% 24%
Giannini <i>et al</i> (2000) <sup>38</sup>	Stable asthma treated with CS, currently asymptomatic	Sputum	3.0% eosinophils	30	33%
Gibson <i>et al</i> (2001) <sup>21</sup>	Persistent asthma, BHR, CS dependent: • Mild persistent • Moderate persistent • Severe persistent	Sputum	2.5% eosinophils	56 11 26 19	41% 27% 46% 42%
Ottanelli <i>et al</i> (2001) <sup>39</sup>	Stable persistent asthma treated with ICS with FEV <sub>1</sub> /FVC <70%	Sputum	2.0% eosinophils	26††	62%
Fahy <i>et al</i> (2001) <sup>40</sup>	Moderate to severe asthma	Sputum	2.0% eosinophils	56‡‡	59%
<i>Studies in children:</i>					
Gibson <i>et al</i> (1998) <sup>20</sup>	Open population incl non-symptomatic subjects: • Symptoms in past 2 weeks‡ • BHR§	Sputum	2.5% eosinophils¶	(162) 56 23	(27%) 41% 62%
Gibson <i>et al</i> (1999) <sup>41</sup>	Acute severe asthma	Sputum	2.5% eosinophils	37	88%
Marguet <i>et al</i> (1999) <sup>19</sup>	• Asthma with recurrent symptoms • Infantile wheezers (age 5–46 months)	BAL	2% eosinophils¶	14 26	57% 19%
Wilson <i>et al</i> (2000) <sup>31</sup>	Asthma of variable severity: • Not treated with ICS • Treated with ICS	Sputum	2% eosinophils¶	36 21 15	19% 29% 7%
Gibson <i>et al</i> (2001) <sup>42</sup>	Asthma defined as wheezing in last 12 months‡	Sputum	2.5% eosinophils	22	45%

\*All asthma cases were recruited from symptomatic patients attending a clinic, unless indicated otherwise; these studies therefore only give a crude estimate of the proportion of asthma which is characterised by lung eosinophilia in selected populations.

†Induced and spontaneous sputum.

‡Children with asthma symptoms not recruited through a clinic.

§Children with bronchial hyperresponsiveness (BHR).

¶In case the authors did not define a cut off or when a cut off of less than 2% was chosen in the original study, we have set the cut off at 2%.

\*\*Cut off was determined based on eosinophil counts in control subjects unless indicated otherwise.


††30 obstructed ICS treated patients were included in the study but in the figure only 26 could be observed. Individual sputum data for the other three asthma groups (ICS treated non-obstructed and ICS naïve obstructed and non-obstructed patients) were not given in the article.

‡‡59 patients were included in the study but in the figure only 56 could be observed.

asthma and suggest what these mechanisms may be. In occupational medicine it has long been recognised that a substantial proportion of work related asthma is non-allergic. One type of non-allergic asthma frequently referred to as “asthma like disorder or syndrome” or “irritant induced asthma”<sup>25–45</sup> may be a useful model for non-allergic asthma in the general population, since it is relatively common in occupational populations and causal exposures are diverse and are often present also in the general environment. It is highly prevalent in farmers and those in farm related occupations, but also in many other occupations with exposures to bio-aerosols containing microbial agents.<sup>45</sup> Although some prefer the term “asthma like syndrome”, it meets the clinical criteria of asthma—that is, reversible airways obstruction. However, in contrast to allergic asthma, previously unexposed subjects can develop symptoms and (reversible) airflow obstruction without any prior sensitisation or latency period,<sup>46–47</sup> and the

underlying inflammation is one in which neutrophils rather than eosinophils dominate.<sup>48–49</sup> Thus, both atopic and non-atopic subjects may develop non-eosinophilic asthma, although atopic subjects may be more sensitive.<sup>50</sup> Moreover, non-allergic occupational asthma is not clearly related to non-specific bronchial hyperresponsiveness,<sup>51</sup> although a transient increase in BHR may be apparent.<sup>46</sup>

Although the exact pathophysiology is not clear, it is well established that non-allergic occupational asthma is mediated by an acute inflammatory response involving a number of cytokines, including IL-1, IL-6, IL-8, and tumour necrosis factor (TNF)- $\alpha$ , and the subsequent massive infiltration and activation of neutrophils in the lower and upper airways<sup>52–54</sup> which is very similar to the inflammatory response observed in non-eosinophilic asthma in the general population (see above). The primary agent inducing these inflammatory responses in



**Figure 1** Acquired and innate immune pathways leading to IL-5 mediated eosinophil (Eos) inflammation (acquired pathway) or IL-8 mediated neutrophil (Pmn) inflammation (innate pathway) and subsequent asthma. Receptors for triggers (FcRI, FcRII, TLR4, CD14) and transcription factors (NFAT, API, GATA, NF-κB) are shown as intermediate steps.

workers exposed to organic dust is believed to be bacterial endotoxin. Macrophages carry specific endotoxin binding receptors (CD14, TLR4) that play a crucial role in the activation of these cells and the subsequent inflammatory reactions.<sup>55, 56</sup>

### RELEVANT EXPOSURES

Which exposures may contribute to the development of non-eosinophilic asthma in the general population? Several non-allergenic exposures such as bacterial endotoxins, particulate air pollution, and ozone which are commonly present in the environment have been shown, both in experimental and epidemiological studies, to induce neutrophilic airway inflammation, airway obstruction, and symptoms of asthma.<sup>57-67</sup> Endotoxin, a strong proinflammatory cell wall component from Gram negative bacteria,<sup>56</sup> has been recognised as an important factor in the aetiology of occupational lung diseases including non-allergic asthma.<sup>45, 57</sup> In addition, it has been shown that endotoxin in house dust is associated with exacerbations of pre-existing asthma in children and adults.<sup>68-71</sup> Finally, one recent birth cohort study in 499 infants with a familial predisposition to asthma or allergy reported that early exposure to indoor endotoxin was associated with an increased risk of repeated wheeze during the first year of life (RR=1.6, 95% CI 1.03 to 2.38).<sup>72</sup> Thus, despite a recent hypothesis that exposure to endotoxin early in life may have a protective effect on the development of atopy and thus potentially also on allergic asthma by enhancing Th1 immunity,<sup>73-76</sup> a role for endotoxin as a risk factor for non-allergic asthma cannot be excluded; in fact, it seems likely.<sup>77</sup>

Ozone is a powerful oxidant and air pollutant that has been shown to exacerbate pre-existing asthma,<sup>78-83</sup> but some evidence from large epidemiological studies has been presented that suggests a role for ozone also in the primary causation of asthma.<sup>84-86</sup> Similarly, particulates such as diesel exhaust increase asthma symptoms, induce neutrophilic airways inflammation,<sup>84</sup> and promote neutrophil mobilisation from the bone marrow.<sup>65</sup> These responses are most probably mediated by NF-κB activation and IL-8 secretion.<sup>87</sup> Thus ozone, particulates, and endotoxin have the potential to induce asthma by non-allergic mechanisms and, while they are commonly present in increased concentrations in the environment, they may contribute to the development of non-eosinophilic asthma in the general population.

In addition, viral infections may induce non-eosinophilic asthma. Viral respiratory tract infections are the most common cause of significant asthma exacerbations in children<sup>88</sup> and adults.<sup>89</sup> As for endotoxin, particulates, and

ozone, viral infection of respiratory epithelial surfaces promotes a vigorous chemokine response with increased IL-8 secretion that is believed to be responsible for the typical neutrophil inflammation in viral induced asthma.<sup>90</sup>

### ROLE OF INNATE IMMUNE ACTIVATION

The common pathophysiological features of non-eosinophilic asthma involve an IL-8 mediated neutrophil influx and the subsequent neutrophil activation is a potent stimulus to increased airway hyperresponsiveness.<sup>91</sup> Although the stimuli that trigger this response are diverse (endotoxin, ozone, particulates, virus infection), the common features are consistent with activation of innate immune mechanisms rather than IgE mediated activation of acquired immunity. Recent data indicate a role for Toll-like receptors (TLR) and CD14 in this process.<sup>92</sup> TLRs can recognise a large variety of chemically diverse stimuli which then trigger proinflammatory responses involving NF-κB activation and chemokine production<sup>93, 94</sup> characteristic of non-eosinophilic asthma (fig 1).

There is also the potential for combined activation of both innate and allergen specific inflammatory mechanisms to occur in asthma. This could result in a mixed eosinophil/neutrophil response as has been observed in some cases of acute asthma,<sup>41</sup> and may explain the ability of ozone and NO<sub>2</sub> to potentiate allergen induced asthmatic responses.<sup>95</sup>

### CONCLUSIONS

We have previously shown that atopic mechanisms may account for, at most, "only" 40% of cases of asthma in the general population.<sup>4</sup> Interestingly, in this review we have shown that, at most, "only" 50% of all asthma cases are attributable to eosinophilic airway inflammation. Thus, evidence from studies of eosinophilia and asthma is consistent with that from studies of atopy and asthma: in both instances, at most about 50% of asthma cases appear to be due to "allergic" mechanisms (whether these are defined in terms of atopy or in terms of eosinophilia). This further adds to the evidence that allergic mechanisms may not be the only and/or necessarily the most important underlying mechanism for asthma. Non-eosinophilic asthma is associated with neutrophilic responses not only in severe asthmatics but also in those with moderate and mild asthma, and we thus hypothesise that a major proportion of asthma is based on neutrophilic airway inflammation. Environmental exposure to bacterial endotoxin, particulate air pollution, and ozone, as well as viral infections, may play an important role as triggers of neutrophilic airway inflammation in asthma.

The inflammatory picture in surveys of the general population appears to be very similar to that observed in non-allergic asthma in occupational populations which thus may serve as a suitable model for non-allergic asthma in the general population. It is not clear whether neutrophilia develops as a primary pathological process (as is the case in occupational non-allergic asthma) or is secondary to high doses of inhaled corticosteroids (ICS) that are known to prolong the survival of neutrophils<sup>96</sup> and to reduce eosinophil survival.<sup>97</sup> One study<sup>38</sup> seems to confirm the latter hypothesis to a certain extent; after cessation of treatment with ICS the percentage of eosinophils increased significantly in seven of 20 subjects with recurrent symptoms but only marginally in the 13 subjects without recurrence of asthma symptoms (not significant). Furthermore, two studies<sup>31, 37</sup> indicated a lower proportion of eosinophilic asthmatic subjects in those receiving ICS. However, in these two studies the prevalence was still relatively low even in those who did not receive treatment with ICS (67% and 29%, respectively). In addition, in the study by Gibson *et al*<sup>20</sup> only six of the 56 asthmatic children were on ICS but the percentage of eosinophilic asthma was “only” 41%. In the study by Ottanelli *et al*<sup>39</sup> no difference was seen in the mean proportion of eosinophils in the obstructed ICS naïve and ICS treated asthma patients. Finally, several other studies<sup>24, 43</sup> showed that corticosteroid treatment was unlikely to explain the differences in inflammatory responses since no difference in treatment existed between the groups with and without increased bronchial eosinophilic cells. However, regardless of the exact mechanisms involved, neutrophils appear to be important in the pathophysiology of asthma, both in occupational populations and in the general population. The features suggest a common mechanism involving activation of innate immune responses in the generation of chemokine release and neutrophil influx.

Our focus has been on assessing the relative importance of non-eosinophilic mechanisms for asthma and on the need for more research into what these mechanisms may be. Nevertheless, on the basis of current evidence it is tempting to speculate that most non-eosinophilic asthma is neutrophil mediated, in contrast to allergic asthma which is eosinophil mediated. If there are indeed two (or more) subtypes of asthma as hypothesised, and if non-eosinophilic (neutrophil mediated) asthma is relatively common, this would have major consequences for the treatment and prevention of asthma since most treatment and prevention strategies are now almost entirely focused on allergic/eosinophilic asthma and allergen avoidance measures, respectively. It is therefore important to study the aetiology of asthma further, including the underlying inflammatory profiles. Furthermore, since little is known about the prognosis of both types of asthma, future studies need prospective evaluation. A better understanding of the underlying mechanisms will also provide a firmer basis for new theories to explain why there is a world wide increase in asthma, and would provide new insights into which factors determine primary causation of asthma. The current “hygiene hypothesis”, which is based on the assumption that a lack of certain exposures early in life (for example, infections) may enhance Th2 or atopic immune responses,<sup>74</sup> can potentially only explain an increase in *allergic* but not of *non-allergic* asthma. Thus, with the large proportion of non-allergic asthma it is questionable whether the “hygiene hypothesis” (as defined above) on its own can explain the large increase observed over the last decades.

#### ACKNOWLEDGEMENTS

The Centre for Public Health Research is funded by the Health Research Council of New Zealand. Jeroen Douwes is supported by a research fellowship from the Netherlands Organization for Scientific Research (NWO).

#### Authors' affiliations

**J Douwes**, Institute for Risk Assessment Sciences (IRAS), Division of Environmental and Occupational Health, Utrecht University, The

Netherlands

**P Gibson**, Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, Australia

**J Pekkanen**, National Public Health Institute, Unit of Environmental Epidemiology, Kuopio, Finland

**J Douwes, N Pearce**, Centre for Public Health Research, Massey University Wellington Campus, Wellington, New Zealand

#### REFERENCES

- 1 **Pearce N**, Douwes J, Beasley R. The rise and rise of asthma: a new paradigm for the new millennium. *J Epidemiol Biostat* 2000;**5**:5–16.
- 2 **Global Initiative for Asthma (GINA)**. *Global strategy for asthma management and prevention*. NHLBI/WHO Workshop Report. Washington DC: NIH, 1995.
- 3 **Cambell P**, Weiss U, eds. Allergy and asthma. *Nature* 1999;**402**:B1–38.
- 4 **Pearce N**, Pekkanen J, Beasley R. How much asthma is really attributable to atopy? *Thorax* 1999;**54**:268–72.
- 5 **Pearce N**, Douwes J, Beasley R. Is allergen exposure the major cause of asthma? *Thorax* 2000;**55**:424–31.
- 6 **Priftanji A**, Strachan D, Burr M, *et al*. Asthma and allergy in Albania and the UK. *Lancet* 2001;**358**:1426–7.
- 7 **Fahy JV**, Fleming HE, Wong HH, *et al*. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. *Am J Respir Crit Care Med* 1997;**155**:1828–34.
- 8 **Boulet LP**, Chapman KR, Cote J, *et al*. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. *Am J Respir Crit Care Med* 1997;**155**:1835–40.
- 9 **Fahy JV**, Cockcroft DW, Boulet LP, *et al*. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. *Am J Respir Crit Care Med* 1999;**160**:1023–7.
- 10 **Casale TB**, Bernstein IL, Busse WW, *et al*. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. *J Allergy Clin Immunol* 1997;**100**:110–21.
- 11 **Milgrom H**, Fick RB Jr, Su JQ, *et al*. Treatment of allergic asthma with monoclonal anti-IgE antibody. Rhumab-E25 Study Group. *N Engl J Med* 1999;**341**:1966–73.
- 12 **Salvi SS**, Babu KS. Treatment of allergic asthma with monoclonal anti-IgE antibody. *N Engl J Med* 2000;**342**:1292–3.
- 13 **Salvi SS**. Glucocorticoids enhance IgE synthesis. Are we heading towards new paradigms? *Clin Exp Allergy* 2000;**30**:1499–505.
- 14 **Mehlhof PD**, van de Rijn M, Goldberg AB, *et al*. Allergen-induced bronchial hyperreactivity and eosinophilic inflammation occur in the absence of IgE in a mouse model of asthma. *Proc Natl Acad Sci USA* 1997;**94**:1344–9.
- 15 **Hamelmann E**, Takeda K, Schwartz J, *et al*. Development of eosinophilic airway inflammation and airway hyperresponsiveness requires interleukin-5 but not immunoglobulin E or B lymphocytes. *Am J Respir Cell Mol Biol* 1999;**21**:480–9.
- 16 **Hamelmann E**, Cieslewicz, Schwarze J, *et al*. Anti-interleukin 5 but not anti-IgE prevents airway inflammation and airway hyperresponsiveness. *Am J Respir Crit Care Med* 1999;**160**:934–41.
- 17 **Tournoy KG**, Kips JC, Schou C, *et al*. Airway eosinophilia is not a requirement for allergen-induced airway hyperresponsiveness. *Clin Exp Allergy* 2000;**30**:79–85.
- 18 **Wenzel SE**, Schwartz LB, Langmack EL, *et al*. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. *Am J Respir Crit Care Med* 1999;**160**:1001–8.
- 19 **Marguet C**, Jouen-Boedes F, Dean TP, *et al*. Bronchoalveolar cell profiles in children with asthma, infantile wheeze, chronic cough, or cystic fibrosis. *Am J Respir Crit Care Med* 1999;**159**:1533–40.
- 20 **Gibson PG**, Wlodarczyk JW, Hensley MJ, *et al*. Epidemiological association of airway inflammation with asthma symptoms and airway hyperresponsiveness in childhood. *Am J Respir Crit Care Med* 1998;**158**:36–41.
- 21 **Gibson PG**, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. *Chest* 2001;**119**:1329–36.
- 22 **Pavord ID**, Brightling CE, Woltmann G, *et al*. Non-eosinophilic corticosteroid unresponsive asthma. *Lancet* 1999;**353**:2213–4.
- 23 **Jatakanon A**, Uasuf C, Maziak W, *et al*. Neutrophilic inflammation in severe persistent asthma. *Am J Respir Crit Care Med* 1999;**160**:1532–9.
- 24 **Turner MO**, Hussack P, Sears MR, *et al*. Exacerbations of asthma without sputum eosinophilia. *Thorax* 1995;**10**:1057–61.
- 25 **Bernstein IL**, Chan-Yeung M, Malo JL, *et al*, eds. *Asthma in the workplace*. 2nd ed. New York: Marcel Dekker, 1999: 742 pp.
- 26 **Gibson PG**. Use of induced sputum to examine airway inflammation in childhood asthma. *J Allergy Clin Immunol* 1998;**102**:s100–1.
- 27 **Pizzichini E**, Pizzichini MM, Efthimiadis A, *et al*. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. *Am J Respir Crit Care Med* 1996;**154**:308–17.
- 28 **Holt PG**, Macaubas C, Stumbles PA, *et al*. The role of allergy in the development of asthma. *Nature* 1999;**402**:B12–7.
- 29 **Pin I**, Gibson PG, Kolendovicz R, *et al*. Use of induced sputum cell counts to investigate airway inflammation in asthma. *Thorax* 1992;**47**:25–9.
- 30 **Berlyne GS**, Efthimiadis A, Hussack P, *et al*. Sputum in asthma: color versus cell counts. *J Allergy Clin Immunol* 1999;**104**:182–3.

- 31 **Wilson NM**, Bridge P, Spanevello A, *et al*. Induced sputum in children: feasibility, repeatability and relation of findings to asthma severity. *Thorax* 2000;**55**:768–74.
- 32 **Fahy JV**, Kim KW, Liu J, *et al*. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. *J Allergy Clin Immunol* 1995;**95**:843–52.
- 33 **Pavord ID**, Ward R, Woltmann G, *et al*. Induced sputum eicosanoid concentrations in asthma. *Am J Respir Crit Care Med* 1999;**160**:1905–9.
- 34 **Lemière C**, Pizzichini MMM, Balkissoon R, *et al*. Diagnosing occupational asthma: use of induced sputum. *Eur Respir J* 1999;**13**:482–8.
- 35 **Tarodo de la Fuente P**, Romagnoli M, Carlsson L, *et al*. Eosinophilic inflammation assessed by induced sputum in corticosteroid-dependent asthma. *Respir Med* 1999;**93**:183–9.
- 36 **Ordoñez CL**, Shaughnessy TE, Matthay MA, *et al*. Increased neutrophil numbers and IL-8 levels in airway secretions in acute severe asthma. *Am J Respir Crit Care Med* 2000;**161**:1185–90.
- 37 **Wark PAB**, Gibson PG, Fakes K. Induced sputum eosinophils in the assessment of asthma and chronic cough. *Respirology* 2000;**5**:51–7.
- 38 **Giannini D**, Di Franco A, Cianchetti S, *et al*. Analysis of induced sputum before and after withdrawal of treatment with inhaled corticosteroids in asthmatic patients. *Clin Exp Allergy* 2000;**30**:1777–84.
- 39 **Ottanelli R**, Rosi E, Romagnolo I, *et al*. Do inhaled corticosteroids affect perception of dyspnea during bronchoconstriction in asthma? *Chest* 2001;**120**:770–7.
- 40 **Fahy JV**, Boushey HA, Lazarus SC, *et al*. Safety and reproducibility of sputum induction in asthmatic subjects in a multicenter study. *Am J Respir Crit Care Med* 2001;**163**:1470–5.
- 41 **Gibson PG**, Norzila MZ, Fakes K, *et al*. Pattern of airway inflammation and its determinants in children with acute severe asthma. *Pediatr Pulmonol* 1999;**28**:261–70.
- 42 **Gibson PG**, Simpson JL, Chalmers AC, *et al*. Airway eosinophilia is associated with wheeze but is uncommon in children with persistent cough and frequent chest colds. *Am J Respir Crit Care Med* 2001;**164**:977–81.
- 43 **Amin K**, Lúdvíksdóttir D, Janson C, *et al*. Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma. *Am J Respir Crit Care Med* 2000;**162**:2295–301.
- 44 **Wenzel SE**, Stanley JS, Leung DYM, *et al*. Bronchoscopic evaluation of severe asthma: persistent inflammation associated with high dose glucocorticoids. *Am J Respir Crit Care Med* 1997;**156**:737–43.
- 45 **Schenker MB**, D Christiani, Y Cormier, *et al*. Respiratory health hazards in agriculture. *Am J Respir Crit Care Med* 1998;**158**:S1–76.
- 46 **Jacobs RR**, Becklake B, van Hage-Hamsten M, *et al*. Bronchial reactivity, atopy, and airway response to cotton dust. *Am Rev Respir Dis* 1993;**148**:19–24.
- 47 **Sepulveda M-J**, Castellán RM, Hankinson JL, *et al*. Acute lung function response to cotton dust in atopic and non atopic individuals. *Br J Ind Med* 1984;**41**:487–91.
- 48 **Larsson BM**, Palmberg L, Malmberg PO, *et al*. Effect of exposure to swine dust on levels of IL-8 in airway lavage fluid. *Thorax* 1997;**52**:638–42.
- 49 **Clapp WB**, Becker S, Quay J, *et al*. Grain dust-induced airflow obstruction and inflammation of the lower respiratory tract. *Am J Respir Crit Care Med* 1994;**150**:611–7.
- 50 **Preller L**, Doekes G, Heederik D, *et al*. Disinfectant use as a risk factor for atopic sensitisation and symptoms consistent with asthma: an epidemiological study. *Eur Respir J* 1996;**9**:1407–13.
- 51 **Enarson DA**, Vedal S, Chan-Yeung M. Fate of grainhandlers with bronchial hyperreactivity. *Clin Invest Med* 1988;**11**:193–7.
- 52 **Becker S**, Clapp WA, Quay J, *et al*. Compartmentalization of the inflammatory response to inhaled grain dust. *Am J Respir Crit Care Med* 1999;**160**:1309–18.
- 53 **Jung KS**, Park HS. Evidence for neutrophil activation in occupational asthma. *Respirology* 1999;**4**:303–6.
- 54 **Lumms ZL**, Alam R, Bernstein JA, *et al*. Diisocyanate antigen-enhanced production of monocyte chemoattractant protein-1, IL-8, and tumor necrosis factor- $\alpha$  by peripheral mononuclear cells of workers with occupational asthma. *J Allergy Clin Immunol* 1998;**102**:265–74.
- 55 **Wright SD**, Ramos RA, Tobias PS, *et al*. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. *Science* 1990;**249**:1431–3.
- 56 **Ulmer AJ**. Biochemistry and cell biology of endotoxins. *Int J Occup Environ Health* 1997;**3**:s8–17.
- 57 **Douwes J**, Heederik D. Epidemiologic investigations of endotoxins. *Int J Occup Environ Health* 1997;**3**:s26–31.
- 58 **Michel O**, Nagy AM, Schroeven M, *et al*. Dose-response relationship to inhaled endotoxin in normal subjects. *Am J Respir Crit Care Med* 1997;**156**:1157–64.
- 59 **Anonymous**. Health effects of outdoor air pollution. Committee of the Environmental and Occupational Health Assembly of the American Thoracic Society. *Am J Respir Crit Care Med* 1996;**153**:3–50.
- 60 **Nightingale JA**, Rogers DF, Barnes PJ. Effect of inhaled ozone on exhaled nitric oxide, pulmonary function, and induced sputum in normal and asthmatic subjects. *Thorax* 1999;**54**:1061–9.
- 61 **Holtz O**, Jorres RA, Timm P, *et al*. Ozone-induced airway inflammatory changes differ between individuals and are reproducible. *Am J Respir Crit Care Med* 1999;**159**:776–84.
- 62 **Basha MA**, Gross KB, Gwizdzala CJ, *et al*. Bronchoalveolar lavage neutrophilia in asthmatic and healthy volunteers after controlled exposure to ozone and filtered purified air. *Chest* 1994;**106**:1757–65.
- 63 **Torres A**, Utell MJ, Morow PE, *et al*. Airway inflammation in smokers and nonsmokers with varying responsiveness to ozone. *Am J Respir Crit Care Med* 1997;**156**:728–36.
- 64 **Nightingale JA**, Maggs R, Cullinan P, *et al*. Airway inflammation after controlled exposure to diesel exhaust particulates. *Am J Respir Crit Care Med* 2000;**162**:161–6.
- 65 **Mukae H**, Vincent R, Quinlan K, *et al*. The effect of repeated exposure to particulate air pollution (PM10) on the bone marrow. *Am J Respir Crit Care Med* 2001;**163**:201–9.
- 66 **Salvi S**, Blomberg A, Rudell B, *et al*. Acute inflammatory responses in the airways and peripheral blood after short-term exposure to diesel exhaust in healthy human volunteers. *Am J Respir Crit Care Med* 1999;**159**:702–9.
- 67 **Nightingale JA**, Rogers DF, Hart LA, *et al*. Effect of inhaled endotoxin on induced sputum in normal, atopic, and atopic asthmatic subjects. *Thorax* 1998;**53**:563–71.
- 68 **Michel O**, Ginanni R, Duchateau J, *et al*. Domestic endotoxin exposure and clinical severity of asthma. *Clin Exp Allergy* 1991;**21**:441–8.
- 69 **Michel O**, Kips J, Duchateau J, *et al*. Severity of asthma is related to endotoxin in house dust. *Am J Respir Crit Care Med* 1996;**154**:1641–6.
- 70 **Rizzo MC**, Naspitz CK, Fernandez-Cladas E, *et al*. Endotoxin exposure and symptoms in asthmatic children. *Pediatr Allergy Immunol* 1997;**8**:121–6.
- 71 **Douwes J**, A Zuidhof, G Doekes, *et al*.  $\beta(1\rightarrow3)$ -glucan and endotoxin in house dust and peak flow variability in children. *Am J Respir Crit Care Med* 2000;**162**:1348–54.
- 72 **Park JH**, Gold DR, Spiegelman DL, *et al*. House dust endotoxin and wheeze in the first year of life. *Am J Respir Crit Care Med* 2001;**163**:322–8.
- 73 **Holt PG**, Sly PD, Bjorksten B. Atopic versus infectious diseases in childhood: a question of balance? *Pediatr Allergy Immunol* 1997;**8**:53–8.
- 74 **Martinez FD**, Holt PG. Role of microbial burden in aetiology of allergy and asthma. *Lancet* 1999;**354**:12–5.
- 75 **Von Mutius E**. The environmental predictors of allergic disease. *J Allergy Clin Immunol* 2000;**105**:9–19.
- 76 **Gereda JE**, Leung DYM, Thatayatikom A, *et al*. Relation between house-dust endotoxin exposure, type 1 T-cell development, and allergen sensitisation in infants at high risk of asthma. *Lancet* 2000;**355**:1680–3.
- 77 **Douwes J**, Pearce N, Heedrik D. Does environmental endotoxin exposure prevent asthma? *Thorax* 2002;**57**:86–90.
- 78 **Lebowitz MD**, Collins L, Holberg CJ. Time series analyses of respiratory responses to indoor and outdoor environmental phenomena. *Environ Res* 1987;**43**:332–41.
- 79 **Kreit JW**, Gross KB, Moore TB, *et al*. Ozone-induced changes in pulmonary function and bronchial responsiveness in asthmatics. *J Appl Physiol* 1989;**66**:217–22.
- 80 **Weisel CP**, Cody RP, Liou PJ. Relationship between summertime ambient ozone levels and emergency department visits for asthma in central New Jersey. *Environ Health Perspect* 1995;**103**:97–102.
- 81 **Scannell C**, Chen L, Aris RM, *et al*. Greater ozone-induced inflammatory responses in subjects with asthma. *Am J Respir Crit Care Med* 1996;**154**:24–9.
- 82 **Thurston GD**, Lippmann M, Scott MB, *et al*. Summertime haze air pollution and children with asthma. *Am J Respir Crit Care Med* 1997;**155**:654–60.
- 83 **Jalaludin BB**, Chey T, O'Toole BJ, *et al*. Acute effects of low levels of ambient ozone on peak expiratory flow rate in a cohort of Australian children. *Int J Epidemiol* 2000;**29**:549–57.
- 84 **Dockery DW**, Speizer FE, Stram DO, *et al*. Effects of inhalable particles on respiratory health of children. *Am Rev Respir Dis* 1989;**139**:587–94.
- 85 **Greer J**, Abbey DE, Burchette RJ. Asthma related to occupational and ambient air pollutants in non-smokers. *J Occup Med* 1993;**35**:909–15.
- 86 **McDonnell WF**, Abbey DE, Naomi Nishino, *et al*. Long-term ambient ozone concentrations and the incidence of asthma in nonsmoking adults: The Ahsmog study. *Environ Res* 1999;**80**:110–21.
- 87 **Kennedy T**, Ghio AJ, Reed W, *et al*. Copper-dependent inflammation and nuclear factor-kappaB activation by particulate air pollution. *Am J Respir Cell Mol Biol* 1998;**19**:366–78.
- 88 **Johnston SL**. The role of viral and atypical bacterial pathogens in asthma pathogenesis. *Pediatr Pulmonol Suppl* 1999;**18**:141–3.
- 89 **Nicholson KG**, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. *BMJ* 1993;**307**:982–6.
- 90 **Norzilla M**, Fakes K, Henry RL, *et al*. IL-8 secretion and neutrophil recruitment accompanies induced sputum eosinophil activation in children with acute asthma. *Am J Respir Crit Care Med* 2000;**161**:769–74.
- 91 **Anticevich SZ**, Hughes JM, Black JL, *et al*. Induction of hyperresponsiveness in human airway tissue by neutrophils: mechanism of action. *Clin Exp Allergy* 1996;**26**:549–56.
- 92 **Reed CE**, Milton DK. Endotoxin-stimulated innate immunity: a contributing factor for asthma. *J Allergy Clin Immunol* 2001;**108**:157–66.
- 93 **Kurt-Jones EA**, Popova L, Kwinn L, *et al*. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. *Nature Immunol* 2000;**1**:398–401.
- 94 **Kleeberger SR**, Reddy SP, Zhang LY, *et al*. Toll-like receptor 4 mediates ozone-induced murine lung hyperpermeability via inducible nitric oxide synthase. *Am J Physiol Lung Cell Mol Physiol* 2001;**280**:L326–33.
- 95 **Jenkins HS**, Devalia JL, Mister RL, *et al*. The effect of exposure to ozone and nitrogen dioxide on the airway response of atopic asthmatics to inhaled allergen: dose- and time-dependent effects. *Am J Respir Crit Care Med* 1999;**160**:33–9.
- 96 **Cox G**. Glucocorticoid treatment inhibits apoptosis in human neutrophils: separation of survival and activation outcomes. *J Immunol* 1995;**154**:4719–25.
- 97 **Woolley KL**, Gibson PG, Carty K, *et al*. Eosinophil apoptosis and the resolution of airway inflammation in asthma. *Am J Respir Crit Care Med* 1996;**154**:237–43.